Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Calithera Biosciences, Inc
Participants enrolled in this trial will be randomised into one of two arms. In the experimental arm, CB-839 will be given orally twice daily and cabozantinib once daily. In the comparator arm a placebo will be given orally twice daily and cabozantinib once daily.